Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to -$184.1 million.

  • Revolution Medicines' Net Cash Flow fell 14674.1% to -$184.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.2 million, marking a year-over-year increase of 11158.71%. This contributed to the annual value of -$152.4 million for FY2024, which is 12843.44% down from last year.
  • According to the latest figures from Q3 2025, Revolution Medicines' Net Cash Flow is -$184.1 million, which was down 14674.1% from $69.1 million recorded in Q2 2025.
  • Revolution Medicines' 5-year Net Cash Flow high stood at $342.6 million for Q4 2024, and its period low was -$407.7 million during Q1 2024.
  • Moreover, its 5-year median value for Net Cash Flow was -$17.5 million (2022), whereas its average is $6.2 million.
  • The largest annual percentage gain for Revolution Medicines' Net Cash Flow in the last 5 years was 255438.6% (2023), contrasted with its biggest fall of 66735.27% (2023).
  • Over the past 5 years, Revolution Medicines' Net Cash Flow (Quarter) stood at -$20.0 million in 2021, then rose by 12.37% to -$17.5 million in 2022, then skyrocketed by 2030.45% to $338.4 million in 2023, then grew by 1.25% to $342.6 million in 2024, then crashed by 153.72% to -$184.1 million in 2025.
  • Its last three reported values are -$184.1 million in Q3 2025, $69.1 million for Q2 2025, and -$209.5 million during Q1 2025.